Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02034422 · ClinicalTrials.gov registry record · NA

Understanding the Exercise-Hypertension Paradox

A NA study of Hypertension, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
75
Enrollment target
1
Study location

NCT02034422: Completed NA study of Hypertension, sponsored by VA Office of Research and Development.

NCT02034422 is a NA study of Hypertension that has completed, run by VA Office of Research and Development. The registered enrollment target is 75 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02034422, a NA study of Hypertension, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
75 participants
Enrollment target
1
Study location

Study Summary

Hypertension affects 37% of the Veteran population, making it the most common medical condition treated by the VA Health Care System. Physical activity is the first line of defense in the treatment and management of hypertension. However, individuals with hypertension have impaired muscle blood flow and exhibit exaggerated increases in blood pressure during exercise (exercise pressor reflex or EPR) leading to exercise intolerance and increased risk of stroke and heart attack. The cause of these impairments is not known, but it is highly likely that free radical production and the subsequent increase in oxidative stress plays a significant role. Two aims are proposed; Aim 1 will identify the physiological consequences of elevated oxidative stress in hypertension, and Aim 2 will utilize an antioxidant treatment to ameliorate the effects of an exaggerated EPR allowing the safe performance of a clinical exercise rehabilitation program which will then, itself, attenuate the EPR and reduce hypertension.

Primary Outcome

Blood pressure with be assessed prior to the study intervention and during exercise (Aim #1). Additionally, blood pressure will be assessed following 8 weeks of exercise rehabilitation

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Oral Antioxidant
  • OTHER Exercise rehabilitation

Study Locations (1)

Utah

  • VA Salt Lake City Health Care System, Salt Lake City, UT - Salt Lake City

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2014-02-01
Est. Completion 2021-12-31
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT02034422 record still lists

NCT02034422 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Oral Antioxidant is the first listed.

NCT02034422 reports a single indexed study location in Utah.

Frequently Asked Questions

What is clinical trial NCT02034422 about?

NCT02034422 is a clinical study titled "Understanding the Exercise-Hypertension Paradox". Hypertension affects 37% of the Veteran population, making it the most common medical condition treated by the VA Health Care System. Physical activity is the first line of defense in the treatment and management of hypertension. However, individuals with hypertension have impaired muscle blood flow...

What is the current status of trial NCT02034422?

This trial is currently completed. It is a NA study. The enrollment target is 75 participants. The study started on 2014-02-01. Estimated completion is 2021-12-31.

What conditions does trial NCT02034422 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT02034422?

The interventions under investigation include: Oral Antioxidant (DIETARY_SUPPLEMENT), Exercise rehabilitation (OTHER).

Who is sponsoring clinical trial NCT02034422?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02034422 being conducted?

This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02034422's enrollment target sits among peer trials

75 323rd of 470 higher than 142 of 470 other Hypertension trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01535430 · 75 participants

    Assessment of Eloquent Function in Brain Tumor Patients

  • NCT01542879 · 75 participants · Phase 1

    Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer

  • NCT02232191 · 75 participants · Phase 2

    Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients

  • NCT02754544 · 75 participants · NA

    Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02034422, the US trial registry maintained by the National Library of Medicine. NCT02034422 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.